Eli Lilly and Co - Public Comps and Valuation Multiples

Eli Lilly and Co Overview

About Eli Lilly and Co

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Founded

1901

HQ

Employees

47K+

Website

lilly.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $63.8B

LTM EBITDA $28.9B

EV

$993B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Eli Lilly and Co Financials

As of December 2025, Eli Lilly and Co reported last 12-month revenue of $63.8B and EBITDA of $28.9B.

In the same period, Eli Lilly and Co generated $53.4B in LTM gross profit and $21.3B in net income.

See Eli Lilly and Co valuation multiples based on analyst estimates

Eli Lilly and Co P&L

In the most recent fiscal year, Eli Lilly and Co reported revenue of $45.0B and EBITDA of $15.2B.

Eli Lilly and Co expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Eli Lilly and Co valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$63.8B	XXX	$45.0B	XXX	XXX	XXX
Gross Profit	$53.4B	XXX	$36.6B	XXX	XXX	XXX
Gross Margin	84%	XXX	81%	XXX	XXX	XXX
EBITDA	$28.9B	XXX	$15.2B	XXX	XXX	XXX
EBITDA Margin	45%	XXX	34%	XXX	XXX	XXX
EBIT	$26.6B	XXX	$17.5B	XXX	XXX	XXX
EBIT Margin	42%	XXX	39%	XXX	XXX	XXX
Net Profit	$21.3B	XXX	$10.6B	XXX	XXX	XXX
Net Margin	33%	XXX	24%	XXX	XXX	XXX
Net Debt	XXX	XXX	$30.4B	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Eli Lilly and Co including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $63.8B. EBITDA for the last twelve months was $28.9B. In the most recent fiscal year, Eli Lilly and Co achieved $45.0B in revenue and $15.2B in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$63.8B	Analyst estimates available to subscribers	$45.0B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$53.4B	Analyst estimates available to subscribers	$36.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	83.7% gross margin	Analyst estimates available to subscribers	81.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$28.9B	Analyst estimates available to subscribers	$15.2B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	45.3% EBITDA margin	Analyst estimates available to subscribers	33.8% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$26.6B	Analyst estimates available to subscribers	$17.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	41.7% EBIT margin	Analyst estimates available to subscribers	38.9% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$21.3B	Analyst estimates available to subscribers	$10.6B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	33.4% net profit margin	Analyst estimates available to subscribers	23.5% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$30.4B	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Eli Lilly and Co

This financial data table provides comprehensive performance metrics for Eli Lilly and Co, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Eli Lilly and Co generated $63.8B in revenue over the last twelve months.
The company achieved $28.9B in EBITDA over the last twelve months.
Gross profit for the last twelve months was $53.4B.
Net income over the last twelve months reached $21.3B.

Fiscal Year Performance

In the most recent fiscal year, Eli Lilly and Co reported $45.0B in total revenue.
Fiscal year EBITDA was $15.2B.
The company maintained a gross profit margin of 81.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 33.8%.
Net profit margin reached 23.5% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Eli Lilly and Co. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Eli Lilly and Co Stock Performance

Eli Lilly and Co has current market cap of $961B, and EV of $993B.

Market Cap Evolution

Eli Lilly and Co Stock Data

As of January 15, 2026, Eli Lilly and Co's stock price is $1073.

See Eli Lilly and Co trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$993B	$961B	XXX	XXX	XXX	XXX	$23.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Eli Lilly and Co Valuation Multiples

Eli Lilly and Co's trades at 15.6x EV/Revenue multiple, and 34.4x EV/EBITDA.

See valuation multiples for Eli Lilly and Co and 15K+ public comps

Eli Lilly and Co Financial Valuation Multiples

As of January 15, 2026, Eli Lilly and Co has market cap of $961B and EV of $993B.

Equity research analysts estimate Eli Lilly and Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Eli Lilly and Co has a P/E ratio of 45.2x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$961B	XXX	$961B	XXX	XXX	XXX
EV (current)	$993B	XXX	$993B	XXX	XXX	XXX
EV/Revenue	15.6x	XXX	15.6x	XXX	XXX	XXX
EV/EBITDA	34.4x	XXX	34.4x	XXX	XXX	XXX
EV/EBIT	37.4x	XXX	37.4x	XXX	XXX	XXX
EV/Gross Profit	18.6x	XXX	n/a	XXX	XXX	XXX
P/E	45.2x	XXX	45.2x	XXX	XXX	XXX
EV/FCF	86.1x	XXX	86.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eli Lilly and Co Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Eli Lilly and Co Margins & Growth Rates

Eli Lilly and Co's last 12 month revenue growth is 20%

Eli Lilly and Co's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.4M for the same period.

Eli Lilly and Co's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Eli Lilly and Co's rule of X is 96% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Eli Lilly and Co and other 15K+ public comps

Eli Lilly and Co Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	20%	XXX	18%	XXX	XXX	XXX
EBITDA Margin	45%	XXX	45%	XXX	XXX	XXX
EBITDA Growth	32%	XXX	84%	XXX	XXX	XXX
Rule of 40	46%	XXX	66%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	96%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$1.0M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	24%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	42%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial